​

Acadia Pharmaceuticals Ownership | Who Owns Acadia Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Acadia Pharmaceuticals Ownership Summary


Acadia Pharmaceuticals is owned by 97.08% institutional investors, 0.33% insiders, and 2.59% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 25.17% of ACAD shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 4.50% of its assets in Acadia Pharmaceuticals shares.

ACAD Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAcadia Pharmaceuticals97.08%0.33%2.59%
SectorHealthcare Stocks 129.40%12.08%-41.48%
IndustryBiotech Stocks 181.71%11.69%-93.40%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Baker bros. advisors lp42.91M25.17%$1.09B
Blackrock funding, inc. /de22.95M13.37%$462.39M
Vanguard group15.15M8.98%$404.76M
Blackrock12.06M7.32%$196.01M
Vanguard portfolio management9.46M5.51%$190.56M
State street7.65M4.46%$154.17M
Rtw investments, lp7.14M4.19%$180.76M
Vanguard capital management5.79M3.37%$116.68M
Geode capital management3.37M1.97%$67.97M
Dimensional fund advisors lp3.37M1.96%$67.83M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Baker bros. advisors lp42.91M5.44%$1.09B
Verdad advisers, lp82.63K2.00%$2.09M
Birchview capital, lp171.00K1.99%$3.45M
Rtw investments, lp7.14M1.54%$180.76M
Braidwell lp1.65M1.54%$41.65M
Nan fung group102.98K1.39%$2.08M
Sphera funds management356.53K1.18%$9.02M
Frazier life sciences management1.44M0.79%$36.39M
Rice hall james & associates618.89K0.76%$15.66M
Tfg asset management gp167.88K0.67%$4.25M

Top Buyers

HolderShares% AssetsChange
Norges bank1.62M0.00%1.62M
Citadel advisors2.18M0.01%1.56M
Goldman sachs group2.58M0.01%1.02M
D. e. shaw1.70M0.02%968.10K
Vanguard portfolio management9.46M0.01%618.67K

Top Sellers

HolderShares% AssetsChange
Palo alto investors lp---2.87M
Pictet asset management sa343.09K0.01%-1.64M
State street7.65M0.00%-1.43M
Ecor1 capital---1.35M
Sixth street partners management company---1.21M

New Positions

HolderShares% AssetsChangeValue
Norges bank1.62M0.00%1.62M$41.07M
Alyeska investment group310.29K0.02%310.29K$7.85M
Schonfeld strategic advisors284.16K0.03%284.16K$7.19M
Orbimed advisors137.00K0.06%137.00K$3.47M
Longaeva partners117.32K0.06%117.32K$2.97M

Sold Out

HolderChange
Curio wealth-1.00
Dunhill financial-2.00
Corecap advisors-4.00
Coppell advisory solutions-4.00
Wealthcollab-5.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20263711.64%166,589,426-1.95%970.99%21617.39%91-18.75%
Jun 30, 20263590.56%166,753,6511.22%971.03%18213.75%108-16.92%
Mar 31, 2026285-18.10%93,214,952-43.97%550.57%127-25.73%102-15.70%
Dec 31, 2025107-69.69%24,070,676-85.64%140.14%52-72.92%38-64.15%
Sep 30, 2025134-59.02%29,202,139-82.81%170.17%67-54.73%41-66.94%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF7.77M4.50%-8.15K
Vanguard MStar Total Stk Mkt Idx Invest4.10M2.38%15.32K
Vanguard Morn Total Stk Mkt Idx Investor4.08M2.38%18.29K
Vanguard Total Stock Mkt Idx Inv4.08M2.38%18.29K
Vanguard US Total Market Shares ETF3.89M2.33%4.42K
iShares Russell 2000 ETF3.26M1.89%-
First Trust NYSE Arca Biotech ETF3.01M1.77%-
Vanguard Small Cap Index2.91M1.69%-48.07K
State Street® SPDR® S&P® Biotech ETF2.65M1.54%69.42K
Vanguard Small Cap Growth Index Inv1.70M0.99%47.42K

Recent Insider Transactions


DateNameRoleActivityValue
Oct 30, 2026Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICERSell$69.34K
Aug 05, 2026Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICERSell$169.64K
Aug 06, 2026Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICERSell$145.00K
Aug 06, 2026Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICERSell$272.60K
Jul 30, 2026Thompson Elizabeth H.Z. EVP, Head of Research & DevSell$1.31K

Insider Transactions Trends


DateBuySell
2026 Q4-1
2026 Q3-5
2026 Q2-6
2026 Q1-10
2025 Q4-3

ACAD Ownership FAQ


Who Owns Acadia Pharmaceuticals?

Acadia Pharmaceuticals shareholders are primarily institutional investors at 97.08%, followed by 0.33% insiders and 2.59% retail investors. The average institutional ownership in Acadia Pharmaceuticals's industry, Biotech Stocks , is 181.71%, which Acadia Pharmaceuticals falls below.

Who owns the most shares of Acadia Pharmaceuticals?

Acadia Pharmaceuticals’s largest shareholders are Baker bros. advisors lp (42.91M shares, 25.17%), Blackrock funding, inc. /de (22.95M shares, 13.37%), and Vanguard group (15.15M shares, 8.98%). Together, they hold 47.51% of Acadia Pharmaceuticals’s total shares outstanding.

Does Blackrock own Acadia Pharmaceuticals?

Yes, BlackRock owns 7.32% of Acadia Pharmaceuticals, totaling 12.06M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 196.01M$. In the last quarter, BlackRock increased its holdings by 393.47K shares, a 3.37% change.

Who is Acadia Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Baker bros. advisors lp is Acadia Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.44% of its assets in 42.91M Acadia Pharmaceuticals shares, valued at 1.09B$.

Who is the top mutual fund holder of Acadia Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Acadia Pharmaceuticals shares, with 4.50% of its total shares outstanding invested in 7.77M Acadia Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools